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1.01 (95% CI 0.99-1.03). The best trials failed to show a sig-
nificant reduction in breast cancer mortality with a relative risk
of 0.97 (95% CI 0.82-1.14). If data from all eligible trials
(excluding flawed studies) are considered then the relative risk
for breast cancer mortality after 13 years is 0.80 (95% CI 0.71-
0.89). However, breast cancer mortality is considered to be an
unreliable outcome and biased in favour of screening. Flaws are
due to differential exclusion of women with breast cancer from
analysis and differential misclassification of cause of death.
Reviewer’s conclusions The currently available reliable evi-
dence does not show a survival benefit of mass screening for
breast cancer (and the evidence is inconclusive for breast can-
cer mortality). Women, clinicians and policy makers should
consider these findings carefully when they decide whether or
not to attend or support screening programs.
The methodologist’s point of view
L. Moja, I. Moshetti, A. Liberati
As the Cochrane Corner hosts analytical comments on
Cochrane systematic reviews (SRs), it is important that read-
ers are comfortable understanding the science of combining
together the results of different studies, including the most
intimidating technical aspects. In this issue we start to cover
a very focused range of concepts/tips related to SRs, from
understanding meta-analysis graphs and all their numbers to
the impact of heterogeneity on SRs.
The Cochrane Collaboration defines a SR as a review of a
clearly formulated question that uses systematic and explic-
it methods to identify, select and critically appraise relevant
research, and to collect and analyse data from the studies
that are included in the review [1].
Some authors use SR and meta-analysis as interchangeable
words. Following the terminology adopted by the Cochrane
Collaboration, SRs and meta-analyses are two distinct enti-
ties. The term SR indicates the entire research process, while
meta-analysis is the statistical technique performed in a SR to
quantitatively combine the results of individual studies. A
meta-analysis may or may not be part of a SR (i.e., a SR of
cognitivistic theories) and may or may not be appropriate
(i.e., when there is an important clinical heterogeneity
between included studies). Therefore, in SRs, when appropri-
ate, authors can perform a meta-analysis allowing a more pre-
cise estimate of the magnitude of the treatment effect. It is not
to simply sum up together the results from different research
and calculate a summary statistic as if it were one big study.
It is to calculate a weighted average of the results across stud-
ies, in a way that ensures that studies with larger sample sizes
and more events contribute more to the overall result.
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Screening for breast cancer with mammography.
Cochrane Database Syst Rev (4):CD001877
Background Mammographic screening for breast cancer
is controversial, as reflected in greatly varying national
policies.
Objectives The objective was to assess the effect of screen-
ing for breast cancer with mammography on mortality and
morbidity.
Search strategy MEDLINE (16 May 2000), The Cochrane
Breast Cancer Group's trial register (24 Jan 2000) and refer-
ence lists. Letters, abstracts and unpublished trials. Authors
were contacted. 
Selection criteria Randomised trials comparing mammo-
graphic screening with no mammographic screening. 
Data collection and analysis Data were extracted by both
authors independently. 
Main results Seven completed and eligible trials involving
half a million women were identified. The two best trials pro-
vided medium-quality data and, when combined, yield a rela-
tive risk for overall mortality of 1.00 (95% CI 0.96-1.05) after
13 years. However, the trials are underpowered for all-cause
mortality, and confidence intervals include a possible worth-
while effect as well as a possible detrimental effect. If data
from all eligible trials (excluding flawed studies) are consid-
ered then the relative risk for overall mortality after 13 years is
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The most commonly used graphical presentation of SR results
is the forest plot, so named because it helps readers to see the
‘forest’of evidence while still being able to focus on the ‘trees’
of individual studies [2]. While less interesting, meta-analysis
graph is a more rigorous name for it.
Basic elements
The basic elements of a meta-analysis graph are: the studies
(boxes); a vertical line; and a diamond (meta-analysis result)
(Fig. 1).
You are interested to know if a special treatment does more
good than harm. Let us imagine that there are three studies
that answered this question. Each study is indicated by a box.
A horizontal line crosses each study box and its extremes
represent the confidence interval of the study estimate, a
measure of how the result of this study might vary with the
play of chance. Indeed you decide to divide a blank sheet
with a central vertical line: studies’ estimates favouring the
treatment over the control lie on the left side, while studies
favouring the control lie on the right. Studies strongly
favouring the treatment are located far from the vertical line,
while studies not showing differences between treatment and
control lie on the line (no-effect line). Estimates on the left-
hand side of the vertical line do not always mean the treat-
ment is better than the control (pay attention to the type of
outcome). The pooled effect is the last element and is pre-
sented as a diamond at the bottom. The diamond horizontal
ends are its confidence interval.
A ‘hay fever’ example
In a recent review Calderon et al. aimed at evaluating the
efficacy and safety of injection immunotherapy, compared to
placebo, for reducing symptoms and medication needs in
seasonal allergic rhinitis (‘hay fever’) due to tree, grass or
weed pollens [3]. Specific allergen immunotherapy is most
commonly administered as subcutaneous injections by spe-
cialists requiring a building-up period followed by a mainte-
nance period of three to five years.
Fifty-one studies satisfied their inclusion criteria (2871 partici-
pants, 1645 in the treatment groups and 1226 in the placebo).
The duration of treatment varied from three days to three years.
In Figure 2 we present the results of the medication use (typi-
cally a daily score reflecting use of oral antihistamine tablets
entered on a diary card and subsequently totalled and aver-
aged). In this meta-analysis 13 studies considering concurrent
use of anti-allergic medication were pooled (including 549 par-
ticipants treated with active immunotherapy and 414 treated
with placebo). Sample size of single studies is presented as
well as the percentage weight given to the studies in the pooled
analysis. The study boxes vary in size because they are propor-
tional to the percentage weight.
The summary statistic is the standardised difference, which
is a difference in means used when the trials all assess the
same outcome (medication score) using different scales. The
diamond at the bottom of Figure 2 is centred on the midpoint
of the area of overlap of confidence intervals around the esti-
mates of the individual trials. In this example the primary
aim of a meta-analysis becomes clear: to include enough
studies (not all significant by themselves) to narrow the con-
fidence interval around the pooled estimate. Its confidence inter-
val line does not cross the vertical line. Thus we can be confi-
Fig. 2 Review: allergen injection immunotherapy for seasonal aller-
gic rhinitis. Comparison: active treatment vs. placebo. Outcome:
medication score. We have simplified Calderon et al.’s original
analysis 01.02 [3]
Fig. 1 Sample of a hypothetical meta-analysis graph
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dent of the benefit for our patients treated with active
immunotherapy. In numbers the standardised difference fol-
lowing immunotherapy was –0.57 (95% CI –0.82 to –0.33),
indicating a significant reduction (test for overall effect
p<0.00001) in medication scores.
This review has shown that injection immunotherapy in suit-
ably selected patients with hay fever results in significant
reductions in medication use and symptom scores (data not
presented) [1]. Injection immunotherapy has a known and rel-
atively low risk of severe adverse events. This review found that
the treatment was safe, with serious adverse reactions to the
therapy occurring in only four patients (one of whom had been
given a placebo) and adrenaline use only in 19 patients out of
14 085 injections. This low risk of life-threatening adverse
reactions makes this treatment feasible only in hospitals that
have full resuscitation back-up. The risk of an adverse reaction
is increased in asthma sufferers, particularly if poorly con-
trolled. For these reasons, many countries do not recommend
immunotherapy in people with asthma, which excludes a large
proportion of the population that might otherwise benefit.
The meta-analysis graph is a simple and clear way to give read-
ers a visual assessment of results within studies and an overall
pooled estimate. Although the meta-analysis graph helps to
summarise the relative variability observed across trials, it may
be still problematic to interpret the overall average effect size,
because of two reasons. First, we may approach a meta-analy-
sis in which the differences in the participants, interventions or
outcomes (i.e., measurement scales) among studies are so
important that a combined estimate is not a meaningful
description of the set of studies. These differences are referred
to as heterogeneity and will be covered in the next issue of this
journal. Second, the meta-analysis graph does not solve diffi-
culties in interpreting statistical measures: in our case the stan-
dardised difference reports the results in units of standard devi-
ation rather than in units of any of the measurement scales used
in the primary trials, leaving to the reader the mysterious extent
of the magnitude of the effect.
For readers who are interested in learning more about system-
atic reviews, we suggest to freely access the Cochrane Open
Learning Material at http://www.cochrane-net.org/openlearn-
ing [4].
The clinician’s point of view
G.F. Gensini, R. Gusinu
Meta-analysis is widely used in basic research to evaluate the
evidence in different areas, by pharmaceutical companies
to gain approval for new drugs, by clinicians to determine
the most effective course of treatment and by applied
researchers in health and social sciences to plan and justi-
fy new studies.
However, although a meta-analysis can have mathe-
matical precision, in relation to any biases that arise from
the study selection process, it may produce a mathemati-
cally precise, but clinically misleading, result.
Readers of the medical literature must be conscious of the
points of strength and weakness of this technique, consid-
ering the criteria to estimate the methodological quality of
meta-analysis listed below:
- the attention to tracing all the studies, consulting the
data banks of scientific literature;
- the explicitness of the criteria of inclusion of the stud-
ies;
- the appraisal of the methodological quality of the stud-
ies according to reproducibility and defined criteria;
- the homogeneity of the studies; and
- the choice of the outcomes.
In fact the vulnerability of meta-analysis is represented
by:
- publication bias;
- selection bias; and
- heterogeneity.
However, although publication bias has to be considered
of special importance, perhaps as the greatest threat to the
validity of this method, this problem is not an argument
against its use, because such biases exist in the literature
irrespective of whether systematic review or other
methodology is used to summarise research findings.
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